Cancer treatment induced bone loss (CTIBL) is commonly found in patients who get endocrine treatment for breast cancer or patients who get Androgen Deprivation Therapy (ADT) for prostate cancer. The treatment includes luteinizing hormone releasing hormone agonists, gonadotropin-releasing hormone, aromatase inhibitors and anti-androgens.. In CTIBL, patients suffer from severe loss of bone, and the condition is also linked to ageing and menopause in women. It raises the risk of bone fractures in patients suffering from the problem, and the symptoms of the condition are chronic pain, low mobility and reduced survival.
The experts of bone cancer and the researchers at American Society of Clinical Oncology suggest that patients suffering from bone cancer should be given bisphosphonates to reduce the impact of CTIBL. Bisphosphonates, such as zoledronic acid, help in inhibiting bone loss and it also helps the patients suffering from prostate cancer and breast cancer to increase bone mineral density. It helps in improving bone metabolism and bone reabsorption.
Cancer treatment induced bone loss effects patients in the following ways:
Cancer treatment induced bone loss is observed in patients who take hormone therapies for cancer treatment. Hormone therapy is given to patients in early stages of breast cancer or high risk prostate cancer. The therapies provided for breast and prostate cancer lead to the reduction of circulation of oestrogen and testosterone levels in the body, which in turn affects bone metabolism, suppresses bone reabsorption and inhibits bone formation. To treat this condition effectively, patients should be given bisphosphonates as it prevents bone loss and reduces the risks of bone fractures.